The blockbuster weight loss medications that have transformed conversations about obesity and metabolic healthsemaglutide (Ozempic and Wegovy), tirzepatide (Zepbound or Mounjaro), and retatrutide (a newcomer on the block thats not yet FDA approved but highly anticipated for approval next year)are all peptide-based drugs
H.LeeH.KimD.et al (2015)
Contrave follows the same BMI guidelines but is approved for adults onlyits not for use in teens or children
: #ObesityCare #GLP1 #Enobosarm #BodyComposition #LeanMassPreservation #ClinicalTrials #BiotechNews #MetabolicHealth #SARM #WeightManagement #HealthTech #Veru #PrecisionMedicine #DEXA #FunctionalOutcomes Harry Fisch MD Mitchell Steiner, MD, FACS, To view or add a comment, sign in 2025 Exercise Evidence Colleagues, new Endocrine Reviews article on exercise + obesity DATA ALIGNS #ADASOC2026: 150 min/week validated - confirms 20% insulin sensitivity, 0.8% HbA1c #AHA/ACC: Exercise for CVD risk - confirmed across all intensities #AASLD:Exercise first-line for MASLD - validated in just 2 weeks EVIDENCE AHEAD OF GUIDELINES: GLP-1 RA + exercise:60% less regain Bariatric surgery protocols: 5-year pre/post-op data Benefits independent of weight loss:Underemphasized in current standards KEY DATA - COMBINATION THERAPY: GLP-1 RAs + Exercise: Liraglutide + vigorous exercise 4x/week: - 9.5kg loss at 1 year - Only 2.5kg regain vs
P., Cruciani, M., Garaci, E., Chopp, M., & Coccia, E
